Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. - sprookjes - yvandenbroek - TriplyDB

Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.

Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.

http://www.wikidata.org/entity/Q34955582

about

Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity Colistin Dosage without Loading Dose Is Efficacious when Treating Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia Caused by Strains with High Susceptibility to Colistin.Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B.Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa The risk factors of colistin methanesulfonate associated nephrotoxicity.Evaluation of Risk Factors for Intravenous Colistin Use-related Nephrotoxicity p53 Mediates Colistin-Induced Autophagy and Apoptosis in PC-12 Cells.Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.Acute kidney injury-epidemiology, outcomes and economics.Colistin: understanding and applying recent pharmacokinetic advances.Colistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury.Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.A review on colistin nephrotoxicity.Colistin: efficacy and safety in different populations.Strategies for the safe use of colistin.The safety of polymyxin antibiotics.Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care.Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Good tolerability of high dose colistin-based therapy in patients with haematological malignancies.Drug Class Combination-Associated Acute Kidney Injury.Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?Dosing guidance for intravenous colistin in critically-ill patients.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients.Colistin nephrotoxicity in the ICU: Is it different in the geriatric patients?Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients.Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study.Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies.Colistin nephrotoxicity increases with age.A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure.Development of HPLC with fluorescent detection using NBD-F for the quantification of colistin sulfate in rat plasma and its pharmacokinetic applications.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study.

P2860

Q34552966-CE810520-29A5-484B-A04D-5ECA61D51491 Q34596336-6CD59CAE-DD20-402C-9972-90AA89193A85 Q34994417-0304DF73-C5DE-411E-8526-28C09E676432 Q35607925-7DB8B6FF-0670-456E-BC64-635B82683FB0 Q36228369-7CD94088-6A7C-4A5D-92B4-98EB881E00D0 Q36240813-57694C7F-664A-4924-92EA-0EF363835C9E Q36543850-E644D181-B749-4A07-8D45-FC0357CFF097 Q36641728-C430B9EF-01EC-4235-BB86-DC3D5F39AF96 Q36887819-D2014A5B-CB7F-4862-9DCA-3C34937BB263 Q37041117-2CB686CF-40D9-4002-887E-EA95765C4843 Q37053617-6FB132A0-5E92-43E0-9B72-F3C45DE59244 Q37203736-77EE43A5-FB31-437B-AEE0-EE4EC131364C Q37538748-A89EBD87-DD38-4BA3-BA9D-14995B0E1207 Q38180360-25D39E81-A8B4-4325-8A24-D6CBEA38BC52 Q38246001-6B3175CC-9AA8-4C1A-B446-EC6CEFAA17BF Q38252561-A156AA5C-0DE3-422B-8C98-2C1348E221BD Q38416932-A434E299-FFCB-46F0-888E-A26F59C83DB6 Q38501685-F52267F4-9F8F-4553-8682-8E7EBB72DDBA Q38514980-6FCB33D4-D237-4CD3-BB0F-801EBD8C2B33 Q38548658-F05C0287-9070-4F4B-9D2E-B536370200BC Q38586123-8F011A1D-1698-431F-AACA-2CDC505499EC Q38647453-2E6D38E8-C72B-4B37-AE34-322C0FDBACEE Q38677017-F86A9F79-9475-4DA9-B282-81DB47E94D72 Q38790740-03D84D37-0A4F-4AE4-B743-3B21BA0B97E8 Q38869608-A265C8D6-F73A-460E-9956-D90FC788EFAA Q38889504-F2485E6F-CBA6-426D-84D5-522D104A26E8 Q38994000-178EE625-7297-473E-A951-88B969CE6BE7 Q39043757-F1AE7260-F1B9-4BBB-BAC1-90EC875F99C5 Q39067724-A0BD799F-A983-44B6-A3DF-9E064A9B8B6F Q39333751-3D6C5DAA-2B33-4017-BEE3-58ACE40C732A Q40052709-7E9762A4-08FA-4D2F-92C3-DA77AB39347B Q40069157-B96848B8-76C8-4484-93A9-B9E0B1EF4220 Q40911068-48FADF6C-461D-440F-90FB-7CC8309A996C Q41007716-3B7ADEF3-BB85-4C4A-B5EE-C40C580896CE Q41728501-74709F59-63C3-4E7F-BE5F-0935D6171018 Q42204009-5271F3D6-C067-49C6-9E68-62D403D5AC4F Q46328001-739E7CB6-350B-4030-BD95-8A38676C3FCB Q48128185-F008B391-6814-4DCE-8FAA-D40ACDDC748F Q48197188-AB595415-91C2-4577-A03C-7CD05D509D20 Q52640045-9D69F5B9-5A60-4ACE-A502-207E7562AFD3

P2860

Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.

http://www.wikidata.org/entity/Q34955582

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Trough colistin plasma level i ...... ve observational cohort study.

@ast

Trough colistin plasma level i ...... ve observational cohort study.

@en

Trough colistin plasma level i ...... ve observational cohort study.

@nl

type

label

Trough colistin plasma level i ...... ve observational cohort study.

@ast

Trough colistin plasma level i ...... ve observational cohort study.

@en

Trough colistin plasma level i ...... ve observational cohort study.

@nl

prefLabel

Trough colistin plasma level i ...... ve observational cohort study.

@ast

Trough colistin plasma level i ...... ve observational cohort study.

@en

Trough colistin plasma level i ...... ve observational cohort study.

@nl

P1433

Q34955582-62FC0D7C-5884-4A79-8CC0-C897D72CFC9A

P1476

Q34955582-38E17F73-5AF2-4788-98F2-5EF66A8204BA

P2093

Q34955582-0EAC1078-1DFF-422F-B3C2-C70EA63B4BD9

Q34955582-2C652FB2-F9EA-4903-AF4B-AD3B24371C90

Q34955582-3D5280BE-04AB-422B-8974-C5585E29A6B0

Q34955582-4998440C-A044-4441-B6A3-DFB6E5DC46BE

Q34955582-4A4D7222-386B-4CEC-BEE1-17F87954CE89

Q34955582-72117B8A-72DC-46F3-B0F6-5B2466194564

Q34955582-97DED1E2-38BC-4022-ACB5-A894BA4CEE23

Q34955582-DED89BA9-AB70-4650-8E32-A8B00FF30641

Q34955582-EDDEA2B9-D4E4-499E-B311-5B07E23A1787

Q34955582-F32CA490-D5DB-461F-8F79-D82050B0DAAF

P2860

Q34955582-00832A99-CB88-44A8-9BEB-E7FF3C7C533B

Q34955582-09DE42B9-3D21-4282-81DA-8C088F348157

Q34955582-13C07ADA-A232-4A4F-8BEA-345EE36AACFC

Q34955582-14357AAB-83A1-4C68-8E32-9C4C478BB8A6

Q34955582-1F512DC4-5965-4DE2-8578-009654B4166F

Q34955582-26EB0DCA-D0CB-44F2-9064-E2DC987CA835

Q34955582-275F74A3-CCA2-4B00-B480-FB2AE6959717

Q34955582-2C53ECAE-51BF-465F-9649-89727FE15715

Q34955582-34C0882C-FC61-4F7C-8839-E4870278EE69

Q34955582-3E95B547-33EA-4DA2-BDA0-FF964D69AB62

P2888

Q34955582-6038EB00-B913-43D4-A66F-3D1167781494

P304

Q34955582-99C86919-DA60-4830-B62D-D30DA1911AEB

P31

Q34955582-1D1D466F-D708-414D-82A1-8301AB0C7567

P356

Q34955582-742F9E19-5070-4895-A1DA-8743FE1CA68D

P478

Q34955582-9A3D0CE6-CB0E-4E8F-895B-87C5CE3EDB6D

P577

Q34955582-973B3172-1460-4ADB-A1B2-632ACFA33ED5

P5875

Q34955582-235360B2-30E6-46D0-8755-B4319DECE040

P6179

Q34955582-FB32B83C-0AA5-43B2-AC28-4BFE2BF483F4

P698

Q34955582-61702B03-A200-43B1-B8A5-C1705A511A06

P921

Q34955582-178942E4-1D93-48A0-A7C5-EA6B9BFDE9C8

P932

Q34955582-8B6AA91F-C6D3-4BBC-999F-CD65CE718298

P356

1471-2334-13-380

P1433

BMC Infectious Diseases

P1476

Trough colistin plasma level i ...... ve observational cohort study.

@en

P2093

Concepción Segura

http://www.w3.org/2001/XMLSchema#string

Francisco Alvarez-Lerma

http://www.w3.org/2001/XMLSchema#string

Hernando Knobel

http://www.w3.org/2001/XMLSchema#string

Juan P Horcajada

http://www.w3.org/2001/XMLSchema#string

Luisa Sorlí

http://www.w3.org/2001/XMLSchema#string

María Milagro Montero

http://www.w3.org/2001/XMLSchema#string

Natividad Benito

http://www.w3.org/2001/XMLSchema#string

Núria Berenguer

http://www.w3.org/2001/XMLSchema#string

Santiago Grau

http://www.w3.org/2001/XMLSchema#string

Sonia Luque

http://www.w3.org/2001/XMLSchema#string

P2860

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies

Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group

Toxicity after prolonged (more than four weeks) administration of intravenous colistin

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

APACHE II: a severity of disease classification system

Nephrotoxicity of intravenous colistin: a prospective evaluation.

Colistin dosing and nephrotoxicity in a large community teaching hospital.

The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.

Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients

Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria

P2888

1471-2334-13-380

P304

380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2334-13-380

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255984268

http://www.w3.org/2001/XMLSchema#string

P6179

1048745746

http://www.w3.org/2001/XMLSchema#string

P698

23957376

http://www.w3.org/2001/XMLSchema#string

P921

P932

3765824

http://www.w3.org/2001/XMLSchema#string